N-methyl-N-phenyltricyclo[3.3.1.1~3,7~]decane-1-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-N-phenyltricyclo[3.3.1.1~3,7~]decane-1-carboxamide
• 英文别名: N-methyl-N-phenyladamantane-1-carboxamide
• 化学式: C₁₈H₂₃NO
• 分子量: 269.4
• InChiKey: BCFLIXSLOJALTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Pharmaceutical use of substituted amides
  申请人：Andersen Sune Henrik

  公开号：US20060111366A1

  公开（公告）日：2006-05-25

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文介绍了使用取代酰胺来调节11β-羟化甾体脱氢酶1型（11βHSD1）的活性以及将这些化合物用作制药组合物的方法。还介绍了一类新型的取代酰胺，它们在治疗中的应用、包含这些化合物的制药组合物以及它们在药物制剂制造中的应用。这些化合物是11βHSD1的调节剂，更具体地说是抑制剂，可用于治疗、预防和/或预防一系列需要降低活性糖皮质激素细胞内浓度的医学疾病。
• Amide Derivatives and Pharmaceutical Use Thereof
  申请人：Andersen Henrik Sune

  公开号：US20090264414A1

  公开（公告）日：2009-10-22

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟化类固醇脱氢酶1型（11βHSD1）活性以及这些化合物作为药物组分的用途。还描述了一类新型的取代酰胺，它们在治疗中的用途，包括含有这些化合物的药物组分以及它们在制造药物中的用途。这些化合物是调节剂，更具体地说是11βHSD1活性的抑制剂，可用于治疗、预防和/或预防一系列医学疾病，其中降低细胞内活性糖皮质激素的浓度是可取的。
• Cellulose Compound Film, Optical Compensation Sheet, Polarizing Plate, and Liquid Crystal Display Device
  申请人：Nozoe Yutaka

  公开号：US20070259134A1

  公开（公告）日：2007-11-08

  A cellulose compound film containing a cellulose compound having two or more substituents whose polarizability anisotropies Δα calculated by mathematical formula (1) are different from each other, wherein substitution degrees of the following substituents A and B in the cellulose compound satisfy relationship as defined by mathematical formula (A1), in which the substituent A has the lowest Δα and the substituent B has the highest Δα: Δ ⁢ ⁢ α = α ⁢ ⁢ x - α ⁢ ⁢ y + α ⁢ ⁢ z 2 Mathematical ⁢ ⁢ formula ⁢ ⁢ ( 1 ) wherein, in characteristic values obtained after diagonalization of polarizability tensor, αx is the largest component, αy is the second largest component, and αz is the smallest component; DS B 2+ DS B 3− DS B 6≧−0.1   Mathematical formula (A1) wherein DS B 2, DS B 3, and DS B 6 represent a substitution degree of the substituent B at the 2-, 3-, or 6-position of a β-glucose ring constituting unit of cellulose, respectively; and an optical compensation film, a polarizing plate, and a liquid crystal display device, using the cellulose compound film.

  一种纤维素化合物薄膜，其含有具有两个或更多取代基的纤维素化合物，其极化率各向异性Δα通过数学公式（1）计算得出，其中以下取代基A和B的取代度满足数学公式（A1）所定义的关系，其中取代基A具有最低的Δα，而取代基B具有最高的Δα：Δα = αx-αy + αz2数学公式（1）其中，在极化率张量对角化后获得的特征值中，αx是最大分量，αy是第二大分量，αz是最小分量;DSB2 + DSB3-DSB6≥-0.1数学公式（A1）其中DSB2、DSB3和DSB6分别表示取代基B在纤维素构成单位β-葡萄糖环的2-、3-或6-位置的取代度;以及使用该纤维素化合物薄膜的光学补偿膜、偏光板和液晶显示装置。
• Cellulose Acylate Film, Method of Producing the Same, Cellulose Derivative Film, Optically Compensatory Film Using the Same, Optically-Compensatory Film Incorporating Polarizing Plate, Polarizing Plate and Liquid Crystal Display Device
  申请人：Haruta Hiromoto

  公开号：US20090290100A1

  公开（公告）日：2009-11-26

  A method of producing a cellulose derivative film, the method comprising: forming a film with a solvent cast method from a dope including a cellulose derivative satisfying following conditions (a) and (b): (a) at least one among three hydroxyl groups included in a glucose unit of cellulose is substituted by a substituent of which a polarizability anisotropy Δα represented as following Expression (1) is 2.5×10 −24 cm 3 or higher: Expression (1): Δα=αx−(αy+αz)/2, wherein αx, αy and αz is as defined in the specification; and (b) when a substitution degree by a substituent of which Δα is 2.5×10 −24 cm 3 or higher is P A , and a substitution degree by a substituent of which Δα is lower than 2.5×10 −24 cm 3 is P B , the P A and P B satisfy following Expressions (3) and (4): Expression (3): 2P A +P B >3.0; and Expression (4): P A >0.2.

  一种生产纤维素衍生物薄膜的方法，该方法包括：使用包括满足以下条件（a）和（b）的纤维素衍生物的溶胶，通过溶剂浇铸法形成薄膜：（a）纤维素的葡萄糖单元中的三个羟基中的至少一个被取代为极化率各向异性Δα（以下表达式（1）表示）为2.5×10-24cm3或更高的取代基：表达式（1）：Δα=αx-（αy+αz）/ 2，其中αx，αy和αz如规范中定义的；并且（b）当Δα为2.5×10-24cm3或更高的取代基的取代度为PA时，Δα低于2.5×10-24cm3的取代基的取代度为PB，PA和PB满足以下表达式（3）和（4）：表达式（3）：2PA + PB> 3.0；表达式（4）：PA> 0.2。
• Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
  申请人：NOVO NORDISK A/S

  公开号：EP1854487A2

  公开（公告）日：2007-11-14

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。